Trial Profile

EMPACT-MI: A Streamlined, Multicentre, Randomised, Parallel Group, Double-blind Placebo-controlled Superiority Trial to Evaluate the Effect of EMPAgliflozin on Hospitalisation for Heart Failure and Mortality in Patients With aCuTe Myocardial Infarction

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 02 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Apr 2025 Results evaluating empagliflozin treatment in acute myocardial infarction published in the International Journal of Cardiology.
30 Apr 2024 Results published in the Eli lilly media Release showed a 10% relative risk reduction in time to first hospitalization due to heart failure or all-cause mortality for Jardiance versus placebo, which did not reach statistical significance.
06 Apr 2024 According to Eli lilly media release, results presented at the American College of Cardiologys 2024 Scientific Session & Expo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com